Workflow
山河药辅:复星医药减持0.98%公司股份
news flash·2025-06-16 12:23

Core Viewpoint - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., a shareholder holding more than 5% of the shares in Shanhe Pharmaceutical (300452), plans to reduce its holdings by up to 6.978 million shares, representing no more than 3% of the total share capital, between March 18, 2025, and June 15, 2025 [1] Summary by Relevant Sections - Share Reduction Plan - The reduction plan was completed on June 15, 2025, with an average reduction price of 12.54 yuan per share [1] - A total of 2.2828 million shares were reduced, accounting for 0.98% of the total shares [1] - Post-Reduction Holdings - After the reduction, Fosun Pharmaceutical holds 21.6453 million shares, which is 9.23% of the total share capital [1] - Compliance and Business Operations - The reduction plan complies with relevant laws and regulations, and the company's production and operations remain normal, with no change in control [1]